Novel Nanoparticles for Photothermal and Photodynamic Therapy

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (1 December 2022) | Viewed by 3405

Special Issue Editors


E-Mail Website
Guest Editor
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisboa, Av. Professor Gama Pinto, 1649-003 Lisbon, Portugal
Interests: drug delivery systems; lipid-based systems; liposomes; pharmacokinetic studies; biodistribution studies; murine tumor models; cancer; inflammation; melanoma; colon cancer; pancreatic cancer; preclinical studies
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Research Institute for Medicines, iMed.ULisboa—Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal
Interests: development of new drug delivery systems; therapeutic polymers for drug delivery; methods of micro- and nanoencapsulation of drugs
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Photothermal therapy has emerged as a highly promising strategy for the treatment of superficial and localized tumors. It is a minimally invasive technique that takes advantage of the increased sensitivity of cancer cells to heat, relying on the induction of thermal ablation of tumor cells through irradiation with light beams. In addition, it is also considered safe, enabling a faster recovery of the patient compared with other existing therapeutic approaches.

An overview of several nanoparticles for photothermal and photodynamic therapy will be herein presented, with a focus on different methods of preparation and in vitro and in vivo studies, including clinical studies using this nanotechnological approach for cancer management.

Dr. Maria Manuela Gaspar
Dr. Catarina Pinto Reis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • photosensitizing agents
  • photoimmunotherapy
  • lipid-based systems
  • gold nanoparticles
  • polymeric nanoparticles
  • photothermal therapy
  • cancer
  • in vitro and in vivo studies
  • efficacy and safety assessment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

31 pages, 1481 KiB  
Review
How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT
by Joana Lopes, Cecília M. P. Rodrigues, Maria Manuela Gaspar and Catarina Pinto Reis
Pharmaceutics 2022, 14(9), 1817; https://doi.org/10.3390/pharmaceutics14091817 - 29 Aug 2022
Cited by 15 | Viewed by 2848
Abstract
Melanoma is the most aggressive type of skin cancer, the incidence and mortality of which are increasing worldwide. Its extensive degree of heterogeneity has limited its response to existing therapies. For many years the therapeutic strategies were limited to surgery, radiotherapy, and chemotherapy. [...] Read more.
Melanoma is the most aggressive type of skin cancer, the incidence and mortality of which are increasing worldwide. Its extensive degree of heterogeneity has limited its response to existing therapies. For many years the therapeutic strategies were limited to surgery, radiotherapy, and chemotherapy. Fortunately, advances in knowledge have allowed the development of new therapeutic strategies. Despite the undoubted progress, alternative therapies are still under research. In this context, nanotechnology is also positioned as a strong and promising tool to develop nanosystems that act as drug carriers and/or light absorbents to potentially improve photothermal and photodynamic therapies outcomes. This review describes the latest advances in nanotechnology field in the treatment of melanoma from 2011 to 2022. The challenges in the translation of nanotechnology-based therapies to clinical applications are also discussed. To sum up, great progress has been made in the field of nanotechnology-based therapies, and our understanding in this field has greatly improved. Although few therapies based on nanoparticulate systems have advanced to clinical trials, it is expected that a large number will come into clinical use in the near future. With its high sensitivity, specificity, and multiplexed measurement capacity, it provides great opportunities to improve melanoma treatment, which will ultimately lead to enhanced patient survival rates. Full article
(This article belongs to the Special Issue Novel Nanoparticles for Photothermal and Photodynamic Therapy)
Show Figures

Figure 1

Back to TopTop